CLAIMS

1. A polypeptide comprising at least two of:

a) a first polypeptide consisting of the amino acid sequence of SEQ ID NO:10 (D3), SEQ ID NO:36 (D3 sub-fragment), SEQ ID NO: 51 (D3+D4H) or SEQ ID NO:53 (D2+D3+D4H);

b) a second polypeptide consisting of the amino acid sequence of SEQ ID NO:14 (D3), SEQ ID NO:38 (D3 sub-fragment), SEQ ID NO:55 (D3+D4H) or SEQ ID NO:57 (D2+D3+D4H);

c) a third polypeptide consisting of the amino acid sequence of SEQ ID NO:18 (D3), SEQ ID NO:40 (D3 sub-fragment), SEQ ID NO:59 (D3+D4H) or SEQ ID NO:61 (D2+D3+D4H);

d) a fourth polypeptide consisting of the amino acid sequence of SEQ ID NO:22 (D3), SEQ ID NO:42 (D3 sub-fragment), SEQ ID NO:63 (D3+D4H) or SEQ ID NO:65 (D2+D3+D4H);

e) a fifth polypeptide consisting of the amino acid sequence of SEQ ID NO:26 (D3), SEQ ID NO:44 (D3 sub-fragment), SEQ ID NO:67 (D3+D4H) or SEQ ID NO:69 (D2+D3+D4H);

f) a sixth polypeptide consisting of the amino acid sequence of SEQ ID NO:30 (D3), SEQ ID NO:46 (D3 sub-fragment), SEQ ID NO:71 (D3+D4H) or SEQ ID NO:73 (D2+D3+D4H);and

g) a seventh polypeptide consisting of the amino acid sequence of SEQ ID NO:34 (D3), SEQ ID NO:48 (D3 sub-fragment), SEQ ID NO:75 (D3+D4H) or SEQ ID NO:77 (D2+D3+D4H);

with the proviso that the polypeptide excludes a polypeptide comprising D1 (SEQ ID NO: 8, 12, 16, 20, 24, 28, or 32).

2. The polypeptide of claim 1, comprising amino acid sequence:

A-{-X-L }$_n$-B

wherein: each X is an amino acid sequence of first polypeptide, second polypeptide, third polypeptide, fourth polypeptide, fifth polypeptide, sixth polypeptide, or seventh polypeptide as defined in claim 1 and wherein each X is a different polypeptide; L is an optional linker amino acid sequence; A is an optional N terminal amino acid sequence; B is an optional C terminal amino acid sequence; n is an integer of 2 or more.

3. The polypeptide of claim 1 or claim 2, comprising an amino acid sequence selected from the group consisting of: SEQ ID NOs: 83, 84, 85, 86 and 87.

4. An immunogenic composition comprising a polypeptide according to any one of claims 1 to 3 and one or more pharmaceutical carrier(s) and/or excipient(s).

5. An immunogenic composition according to claim 4 or a composition comprising a polypeptide according to any one of claims 1 to 3 for use in therapy.

6. An immunogenic composition according to claim 4 or a composition comprising a polypeptide according to any one of claims 1 to 3 for use in the treatment or prevention of a disease and/or infection caused by GBS.

7. An immunogenic composition according to claim 4 or a composition comprising a polypeptide according to any one of claims 1 to 3 for use in the treatment or prevention of meningitis.

8. A nucleic acid comprising a nucleotide sequence encoding a polypeptide of any one of claims 1-3.

9. The nucleic acid of claim 8, comprising a nucleotide sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92 encoding the polypeptide of claim 3.

10. Use of an immunogenic composition according to claim 4 or a composition comprising a polypeptide according to any one of claims 1 to 3 in the manufacture of a medicament for the treatment or prevention of a disease and/or infection caused by GBS.

11. Use of an immunogenic composition according to claim 4 or a composition comprising a polypeptide according to any one of claims 1 to 3 in the manufacture of a medicament for the treatment or prevention of a disease and/or infection caused by meningitis.